CarThera   Report issue

For profit Phase 2 Phase 3
Founded: Paris France (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2019
NCT03744026
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

CarThera

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Gliosarcoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 7